Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

University of Iowa doctoral student Katie Colling is making progress in identifying hormones that are effective at combating uterine cancer.

Research led by a University of Iowa student is opening new doors to potential uterine cancer treatments that could allow ...

"The doctor told me there was no rush, even though the radiology report stated my tumor was 'of concern.' In fact, she was ...

UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), received nearly $3 million in new academic and prevention awards as part of the latest ...

Doctors are calling for investigations to prove whether the release of microplastics from sex toys could be contributing ...

Preliminary research indicates cannabis compounds cannabidiol and Δ9-tetrahydrocannabinol could have potential in treating ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...